Mangiameli G, Cioffi U, Testori A (2022) Lung cancer treatment: from tradition to innovation. Front Oncol 27(12):858242. https://doi.org/10.3389/fonc.2022.858242

Article  Google Scholar 

Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103–109

Article  CAS  PubMed  Google Scholar 

Re Cecconi E, Mangiameli G, De Simone M, Cioffi U, Marulli G, Testori A (2024) Vats lobectomy for lung cancer. What has been the evolution over the time? Front Oncol 13:1268362

Article  PubMed  PubMed Central  Google Scholar 

Rossi A, Di Maio M (2016) Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther 16(6):653–660. https://doi.org/10.1586/14737140.2016.1170596. (Epub 2016 Apr 8 PMID: 27010977)

Article  CAS  PubMed  Google Scholar 

Korucu Aktas P, Baysal I, Yabanoglu-Ciftci S, Lamprecht A, Arica B (2024) Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer. Int J Pharm 650:123703. https://doi.org/10.1016/j.ijpharm.2023.123703

Article  CAS  PubMed  Google Scholar 

Fitzpatrick O, Naidoo J (2021) Immunotherapy for stage III NSCLC: durvalumab and beyond. Lung Cancer (Auckl) 2(12):123–131. https://doi.org/10.2147/LCTT.S305466.PMID:34754256;PMCID:PMC8572112

Article  Google Scholar 

Martin LW, Mehran RJ (2017) Perspectives on the effect of nodal downstaging and its implication of the role of surgery in stage IIIA (N2) non-small cell lung cancer. J Thorac Dis 9:E646–E652

Article  PubMed  PubMed Central  Google Scholar 

Hishida T, Nagai K, Mitsudomi T, Yokoi K, Kondo H, Horinouchi H, Akiyama H, Nagayasu T, Tsuboi M (2010) Japan clinical oncology group salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg 140(5):e69-71. https://doi.org/10.1016/j.jtcvs.2010.06.035

Article  PubMed  Google Scholar 

Li K, Cao X, Ai B, Xiao H, Huang Q, Zhang Z, Chu Q, Zhang L, Dai X, Liao Y (2021) Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy. Thorac Cancer 15:2161–2169. https://doi.org/10.1111/1759-7714.14044

Article  CAS  Google Scholar 

Lococo F, Cancellieri A, Chiappetta M, Leonetti A, Cardillo G, Zanelli F, Mangiameli G, Toschi L, Guggino G, Romano FJ, Leuzzi G, Proto C, Spaggiari L, De Marinis F, Vita E, Ampollini L, Margaritora S, Tiseo M, Bria E (2023) Salvage surgery after first-line alectinib for locally-advanced/metastatic ALK-rearranged NSCLC: pathological response and perioperative results. Clin Lung Cancer 24(5):467–473. https://doi.org/10.1016/j.cllc.2023.03.008. (Epub 2023 Mar 20 PMID: 37061413)

Article  CAS  PubMed  Google Scholar 

Song W, Di S, Liu J, Fan B, Zhao J, Zhou S, Chen S, Dong H, Yue C, Gong T (2020) Salvage surgery for advanced non-small cell lung cancer after targeted therapy: a case series. Thorac Cancer 11(4):1061–1067. https://doi.org/10.1111/1759-7714.13366

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS (2018) Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg 106(1):178–183. https://doi.org/10.1016/j.athoracsur.2018.02.030

Article  PubMed  PubMed Central  Google Scholar 

Etienne H, Fournel L, Mordant P, Delatour BR, Pfeuty K, Frey G, Seguin-Givelet A, Fourdrain A, Lancelin C, Berna P, Legras A, Alifano M, Bagan P, Assouad J (2023) Anatomic lung resection after immune checkpoint inhibitors for initially unresectable advanced-staged non-small cell lung cancer: a retrospective cohort analysis. J Thorac Dis 15(2):270–280

Article  PubMed  PubMed Central  Google Scholar 

Beattie R, Furrer K, Dolan DP, Curioni-Fontecedro A, Lee DN, Frauenfelder T, Hoeller S, Weder W, Bueno R, Opitz I, Swanson S (2021) Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes. Eur J Cardiothorac Surg 60(6):1297–1305. https://doi.org/10.1093/ejcts/ezab340. (PMID: 34331065)

Article  PubMed  Google Scholar 

Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC, Arenberg DA (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e314S-e340S. https://doi.org/10.1378/chest.12-2360. (PMID: 23649445)

Article  CAS  PubMed  Google Scholar 

Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl 1):S31–S34. https://doi.org/10.4103/sja.SJA_543_18

Article  PubMed  PubMed Central  Google Scholar 

Uramoto H (2016) Current topics on salvage thoracic surgery in patients with primary lung cancer. Ann Thorac Cardiovasc Surg 22(2):65–68. https://doi.org/10.5761/atcs.ra.16-00019

Article  PubMed  PubMed Central  Google Scholar 

Godoy LA, Chen J, Ma W, Lally J, Toomey KA, Rajappa P, Sheridan R, Mahajan S, Stollenwerk N, Phan CT, Cheng D, Knebel RJ, Li T (2023) Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. Biomark Res 11(1):7. https://doi.org/10.1186/s40364-022-00444-7.PMID:36650586;PMCID:PMC9847175

Article  PubMed  PubMed Central  Google Scholar 

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518–2527. https://doi.org/10.1200/JCO.19.00934

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro CJ, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937

Article  CAS  PubMed  Google Scholar 

Leonetti A, Minari R, Boni L, Gnetti L, Verzè M, Ventura L, Musini L, Tognetto M, Tiseo M (2021) Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer 22(5):473–477. https://doi.org/10.1016/j.cllc.2021.02.014. (Epub 2021 Feb 24 PMID: 33762169)

Article  CAS  PubMed  Google Scholar 

Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE (2021) Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol 17(31):4045–4055. https://doi.org/10.2217/fon-2021-0549

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertolaccini L, Galetta D, Sedda G, de Marinis F, Spaggiari L (2022) Safety analysis of salvage surgery for advanced stages or metastatic lung cancers. Thorac Cardiovasc Surg 70(3):273–276. https://doi.org/10.1055/s-0041-1730968. (Epub 2021 Jul 7 PMID: 34233366)

Article  PubMed  Google Scholar 

Ohtaki Y, Shimizu K, Suzuki H, Suzuki K, Tsuboi M, Mitsudomi T, Takao M, Murakawa T, Ito H, Yoshimura K, Okada M, Chida M, Japanese Association for Chest Surgery (2021) Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer 153:108–116. https://doi.org/10.1016/j.lungcan.2020.12.037

Article  CAS  PubMed  Google Scholar 

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H, IMpower010 Investigators (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398(10308):1344–1357. https://doi.org/10.1016/S0140-6736(21)02098-5

Article  CAS  PubMed  Google Scholar 

Smith A, Wali A, Montes A, Hadaki M, Harrison-Phipps K, Karapanagiotou EM, Bille A (2022) Salvage pulmonary resection in stages IIIb-IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. J Surg Oncol 125(2):290–298. https://doi.org/10.1002/jso.26691. (Epub 2021 Sep 27 PMID: 34569618)

Article  CAS